Study of JYB1904 (an Anti-immunoglobulin E Antibody) in Healthy Chinese Subjects
Status:
Recruiting
Trial end date:
2023-03-15
Target enrollment:
Participant gender:
Summary
This phase Ia study is meant to evaluate the tolerability, safety, pharmacokinetics,
preliminary pharmacodynamics, and immunogenicity of single-dose JYB1904, an
anti-immunoglobulin E (IgE) antibody, in healthy Chinese subjects.